Dexcom Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
DexCom (DXCM) PT Lowered to $105 at Oppenheimer; 'Buying on Weakness'
July 29, 2022 7:25 AM EDTOppenheimer analyst Steven Lichtman lowered the price target on DexCom (NASDAQ: DXCM) to $105.00 (from $525.00) while maintaining an Outperform rating following weak results. The analyst is buying on weakness.
The analyst commented, "DexCom's 2Q22 sales of $696.2M (+17% y/y) slightly lagged our/Street's... More
DexCom (DXCM) Misses Q2 EPS by 2c
July 28, 2022 4:04 PM EDTDexCom (NASDAQ: DXCM) reported Q2 EPS of $0.17, $0.02 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $696.2 million versus the consensus estimate of $700.45 million.
GUIDANCE:
DexCom sees Q3 2022 revenue of $2.86-2.91 billion, versus the consensus of $2.92... More
